Business
Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth
AUSTIN, Texas, January 12, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following:
About this update from Natera, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":200,"height":200,"url":"https://media.zenfs.com/en/business-wire.com/378a857652dc3f4f6e2cc4266b204ec0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/e.T735MFm8J2w7Suj643TQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTM2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/378a857652dc3f4f6e2cc4266b204ec0","width":200,"height":200}},"lazy":false},{"type":"text","content":"2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera’s financial outlook","length":160,"tagName":"p","attribs":{}},{"type":"text","content":"Additional business updates will be presented at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026","length":118,"tagName":"p","attribs":{}},{"type":"text","content":"AUSTIN, Texas, January 12, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today released preliminary unaudited results for the fourth quarter and full year ended December 31, 2025. The Company expects the following:","length":277,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenues of approximately $660 million in the fourth quarter of 2025 compared to $476 million in the fourth quarter of 2024, an increase of approximately 39%. Total revenues, excluding revenue true-ups, were greater than $600 million.","length":240,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Total revenues of approximately $2.3 billion in the full year 2025 compared to $1.7 billion in the full year 2024, an increase of approximately 35%.","length":148,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approximately 923,600 tests were processed in the fourth quarter of 2025 compared to 792,800 tests in the fourth quarter of 2024, an increase of 17%.","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approximately 3,525,500 tests were processed in the full year 2025 compared to 3,064,600 tests in the full year 2024, an increase of approximately 15%.","length":151,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Approximately 233,300 oncology tests, including approximately 225,300 clinical ...